Pemirolast ophthalmic Pregnancy and Breastfeeding Warnings
Pemirolast ophthalmic is also known as: Alamast
Pemirolast ophthalmic Pregnancy Warnings
Pemirolast ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of skeletal abnormalities and dilation of the renal pelvis and ureters in rats given pemirolast at 20,000 times the usual human dose. There are no controlled data in human pregnancy. Pemirolast undergoes low systemic absorption after ocular administration (average plasma concentration: 0.8 ng/mL). Pemirolast ophthalmic is only recommended for use during pregnancy when benefit outweighs risk.
Pemirolast ophthalmic Breastfeeding Warnings
There are no data on the excretion of pemirolast ophthalmic into human milk. It is excreted into rat milk at concentrations higher than in plasma. Pemirolast undergoes low systemic absorption after ocular administration (0.8 ng/mL). The manufacturer recommends caution when administering pemirolast ophthalmic to nursing women.
See also
References for pregnancy information
- "Product Information. Alamast (pemirolast ophthalmic)." Santen Inc (2001):
References for breastfeeding information
- "Product Information. Alamast (pemirolast ophthalmic)." Santen Inc (2001):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
